Company Encyclopedia
View More
name
Foci Pharmaceutical
002644.SZ
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing and selling of Chinese herbal medicine pieces; and production and sales of medical devices, such as protective masks. In addition, the company exports its products.
3.157 T
002644.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking152/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.29%C
    • Profit Margin6.60%B
    • Gross Margin30.95%C
  • Growth ScoreD
    • Revenue YoY-9.41%D
    • Net Profit YoY27.94%B
    • Total Assets YoY2.12%C
    • Net Assets YoY2.90%C
  • Cash ScoreC
    • Cash Flow Margin1516.18%B
    • OCF YoY-9.41%D
  • Operating ScoreC
    • Turnover0.36C
  • Debt ScoreB
    • Gearing Ratio26.86%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Foci Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 38.0824 million yuan, a year-on-year decrease of 2.54%

    According to the Zhitong Finance APP, Foci Pharmaceutical released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 624 million yuan, a year-on-year decrease of 11.92%. The net profit attributable to shareholders of the listed company was 38.0824 million yuan, a year-on-year decrease of 2.54%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 23.809 million yuan, a year-on-year decrease of 5.45%

    Zhitong·
    SZ
    002644
    -1.43%
    Zhitong·
    SZ
    002644
    -1.43%

    A-share pharmaceutical stocks continue to adjust, CheezhengTTM approaches the limit down, and multiple stocks such as Xintian Pharmaceutical, Hanyu Pharmaceutical, Guilin Sanjin, Foci Pharmaceutical, YIBAI PHARMACEUTICAL, Zhendong Pharmacy, and Cosunter have fallen over 5%

    Wallstreetcn·
    SZ
    300158
    -0.30%
    SZ
    002287
    -0.40%
    SH
    600594
    -1.16%
    Wallstreetcn·
    SZ
    300158
    -0.30%
    SZ
    002287
    -0.40%
    SH
    600594
    -1.16%

    Foci Pharmaceutical: The company currently has no mosquito repellent products

    Foci Pharmaceutical stated on the interactive platform that the company currently has no mosquito repellent products

    Zhitong·
    SZ
    002644
    -1.43%
    Zhitong·
    SZ
    002644
    -1.43%

    Foci Pharmaceutical: In 2024, the net profit is 60.0698 million yuan, a year-on-year decrease of 10.60%

    Foci Pharmaceutical announced that the operating revenue for 2024 is 980 million yuan, a year-on-year decrease of 15.73%; the net profit attributable to shareholders of the listed company is 60.0698 million yuan, a year-on-year decrease of 10.60%; the basic earnings per share is 0.1176 yuan/share, a year-on-year decrease of 10.64%. The company plans to distribute a cash dividend of 0.12 yuan for every 10 shares to all shareholders, with no bonus shares issued and no capital reserve converted into share capital

    Zhitong·
    SZ
    002644
    -1.43%
    Zhitong·
    SZ
    002644
    -1.43%

    Foci Pharmaceutical: Director and Deputy General Manager Wang Yingchun resigns

    Foci Pharmaceutical announced that on March 18, 2025, the company received a written resignation letter from Wang Yingchun, the director and deputy general manager. Wang Yingchun resigned from the positions of director of the eighth board of directors, deputy general manager, and member of the board's strategic committee for personal reasons. After resigning, Wang Yingchun will no longer hold any position in the company

    Zhitong·
    SZ
    002644
    -1.43%
    Zhitong·
    SZ
    002644
    -1.43%
    © 2025 Longbridge｜Disclaimer